• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov10
InflaRx NV released FY2025 Q3 earnings on November 10 Pre-Market EST, actual revenue USD 27.95 K (forecast USD 34.6 K), actual EPS USD -0.2122 (forecast USD -0.1775)
14:30
InflaRx NV released FY2025 9 Months earnings on November 10 Pre-Market (EST), actual revenue USD 74.1K, actual EPS USD -0.6034
14:30
InflaRx N.V. Reports Positive Data for Anti-inflammatory Drug INF904 Phase 2 Study
12:37
Nov7
InflaRx N.V. to Release Preliminary Results of Oral C5aR Inhibitor INF904 Clinical Trial
21:27
Nov3
InflaRx NV to Release FY2025 Q3 Earnings on November 10, Pre-Market EST, Forecast Revenue USD 34.98K, EPS USD -0.1777
00:05
Oct7
Analyst Schwartz Covers Healthcare Industry Stocks
10:41

Schedules & Filings

Schedules
Filings
Nov10
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 27.95 K, Net Income -14.38 M, EPS -0.2122

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 46.16 K, Net Income -16.87 M, EPS -0.249

May7
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -9 M, EPS -0.1421

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MGRT
13.050
+143.93%
+7.700
PCSA
6.680
+122.30%
+3.675
YCBD
2.270
+58.74%
+0.840
ATPC
0.1408
+56.44%
+0.051
VYNE
0.6000
+48.99%
+0.197
ANDG
23.500
+46.88%
+7.500
ISPO
4.170
+46.83%
+1.330
MDLN
41.000
+41.38%
+12.000
CGTL
1.250
+31.30%
+0.298
GLIBR
8.490
+29.03%
+1.910
View More